PMID- 33314000
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 12
IP  - 1
DP  - 2021 Jan
TI  - Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert 
      Opinion from an Indian Panel.
PG  - 133-142
LID - 10.1007/s13300-020-00979-8 [doi]
AB  - The ongoing global pandemic of the coronavirus disease 2019 (COVID-19) has placed 
      a severe strain on the management of chronic conditions like diabetes. Optimal 
      glycemic control is always important, but more so in the existing environment of 
      COVID-19. In this context, timely insulinization to achieve optimal glycemic 
      control assumes major significance. However, given the challenges associated with 
      the pandemic like restrictions of movement and access to healthcare resources, a 
      simple and easy way to initiate and optimize insulin therapy in people with 
      uncontrolled diabetes is required. With this premise, a group of clinical experts 
      comprising diabetologists and endocrinologists from India discussed the 
      challenges and potential solutions for insulin initiation, titration, and 
      optimization in type 2 diabetes mellitus (T2DM) during the COVID-19 pandemic and 
      how basal insulin can be a good option in this situation owing to its unique set 
      of advantages like lower risk of hypoglycemia, ease of training, need for less 
      monitoring, better adherence, flexibility of using oral antidiabetic drugs, and 
      improved quality of life compared to other insulin regimens. The panel agreed 
      that the existing challenges should not be a reason to delay insulin initiation 
      in people with uncontrolled T2DM and provided recommendations, which included 
      potential solutions for initiating insulin in the absence or restriction of 
      in-person consultations; the dose of insulin at initiation; the type of insulin 
      preferred for simplified regimen and best practices for optimal titration to 
      achieve glycemic targets during the pandemic. Practical and easily implementable 
      tips for patients and involvement of stakeholders (caregivers and healthcare 
      providers) to facilitate insulin acceptance were also outlined by the expert 
      panel. Simplified and convenient insulin regimens like basal insulin analogues 
      are advised during and following the pandemic in order to achieve glycemic 
      control in people with uncontrolled T2DM.
FAU - Chawla, Manoj
AU  - Chawla M
AD  - Lina Diabetes Care and Mumbai Diabetes Research Centre, Mumbai, Maharashtra, 
      India. linadiabetes@gmail.com.
FAU - Jain, Sunil M
AU  - Jain SM
AD  - TOTALL Diabetes and Hormone Institute, Indore, Madhya Pradesh, India.
FAU - Kesavadev, Jothydev
AU  - Kesavadev J
AD  - Department of Diabetes, Jothydev's Diabetes Research Centre, Trivandrum, Kerala, 
      India.
FAU - Makkar, Brij M
AU  - Makkar BM
AD  - Dr. Makkar's Diabetes and Obesity Centre, New Delhi, India.
FAU - Viswanathan, Vijay
AU  - Viswanathan V
AD  - M.V. Centre for Diabetes, Chennai, India.
FAU - Tiwaskar, Mangesh
AU  - Tiwaskar M
AD  - Shilpa Medical Research Centre, Mumbai, India.
FAU - Sosale, Aravind R
AU  - Sosale AR
AD  - Diacon Hospital (Diabetes Care and Research Centre), Bangalore, India.
FAU - Negalur, Vijay
AU  - Negalur V
AD  - Dr. Negalur's Diabetes and Thyroid Specialities Center, Thane, India.
FAU - Modi, Kirtikumar D
AU  - Modi KD
AD  - CARE Hospitals, Hyderabad, India.
FAU - Gupta, Mukulesh
AU  - Gupta M
AD  - Udyaan Health Care, Lucknow, India.
FAU - Kumar, Surinder
AU  - Kumar S
AD  - Department of Endocrinology, Sir Ganga Ram Hospital, New Delhi, India.
FAU - Ramakrishnan, Santosh
AU  - Ramakrishnan S
AD  - Magna Centers for Obesity, Diabetes and Endocrinology, Hyderabad, India.
FAU - Deka, Nilakshi
AU  - Deka N
AD  - Apollo Hospitals, Guwahati, Assam, India.
FAU - Roy, Nirmalya
AU  - Roy N
AD  - KPC Medical College and Hospital, Kolkata, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201212
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC7733136
OTO - NOTNLM
OT  - Basal insulin analogues
OT  - COVID-19
OT  - Diabetes
OT  - Insulin degludec
OT  - Insulin detemir
OT  - Insulin glargine 100 U/mL
OT  - Insulin glargine 300 U/mL
OT  - Insulin initiation during pandemic
OT  - Titration
EDAT- 2020/12/15 06:00
MHDA- 2020/12/15 06:01
PMCR- 2020/12/12
CRDT- 2020/12/14 11:04
PHST- 2020/09/22 00:00 [received]
PHST- 2020/11/26 00:00 [accepted]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2020/12/15 06:01 [medline]
PHST- 2020/12/14 11:04 [entrez]
PHST- 2020/12/12 00:00 [pmc-release]
AID - 10.1007/s13300-020-00979-8 [pii]
AID - 979 [pii]
AID - 10.1007/s13300-020-00979-8 [doi]
PST - ppublish
SO  - Diabetes Ther. 2021 Jan;12(1):133-142. doi: 10.1007/s13300-020-00979-8. Epub 2020 
      Dec 12.